Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust growth across its business segments and geographies. Over the 12 months, the firm’s global net revenues reached USD 16.75 billion, up 17.6% year-on-year (YOY) in constant currency terms. During Q4’24, the US major recorded USD 4.56 billion in net revenues, marking a 22.4% increase YOY.
Business Sector Performance
By business sector, MedSurg sales reached USD 1.62 billion after a 12.4% increase during the fourth quarter. Cardiovascular sales surged 28.8% YOY to USD 2.94 billion. These results highlight the strong performance of Boston Scientific’s key business areas.
Geographical Performance
In terms of geography, the US market saw a 30.7% YOY increase to USD 2.89 billion in sales during the same period. Europe, Middle East and Africa (EMEA) sales grew 10.8% YOY to USD 830 million. Asia-Pacific (APAC) sales jumped 11.1% YOY to USD 684 million, while Latin America and Canada (LACA) expanded 4.6% YOY to USD 155 million. Emerging Markets (all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada) generated USD 668 million in sales after a 12.4% increase.
Future Outlook
Boston Scientific’s strong financial performance in 2024 underscores its market leadership and innovation capabilities. The company is well-positioned to continue its growth trajectory, driven by ongoing investments in research and development and strategic market expansion.-Fineline Info & Tech
